PROGRESS IN UREMIC TOXIN RESEARCH: The General Picture of Uremia
Authors:
- 1 July 2009
- journal article
- review article
- Published by Wiley in Seminars in Dialysis
- Vol. 22 (4) , 329-333
Abstract
The clinical presentation and manifestations of uremia that constitute the uremic syndrome are presented. The first descriptions of patients with advanced or “terminal” renal failure who were treated with hemodialysis are evoked to illustrate the wide range of signs and symptoms that are associated even to a moderate decrease in renal function, presently referred to as chronic kidney disease (CKD) stages 3–4. The kidney is a central organ guaranteeing the maintenance of the “milieu intérieur,” where all the cells of the body are generated, develop, proliferate, and die. Chronic kidney disease, by altering the “milieu intérieur,” may alter the metabolism of every type of cell or organ, leading to a wide scope of symptoms. The most frequently observed signs in daily clinical practice are summarized and put into the perspective of the renal physician. Disturbances of ion and water metabolism, hypertension, cardiovascular disease, anemia, mineral and bone disorders, endocrine, inmmunologic and neurologic syndromes are described. The addition of these clinical manifestations defines and describes each uremic patient as a specific individual. The pathophysiologic mechanisms by which each of these signs and symptoms appears and the particular compounds responsible for their occurrence, are described in depth in subsequent chapters of this issue.Keywords
This publication has 27 references indexed in Scilit:
- What is new in uremic toxicity?Pediatric Nephrology, 2008
- Emerging Biomarkers for Evaluating Cardiovascular Risk in the Chronic Kidney Disease PatientClinical Journal of the American Society of Nephrology, 2008
- Review on uremic toxins: Classification, concentration, and interindividual variabilityKidney International, 2003
- Molecular aspects of T – and B-cell function in uremiaKidney International, 2001
- Atherosclerotic cardiovascular disease risks in chronic hemodialysis patientsKidney International, 2000
- High-dose alfacalcidol for anaemia in dialysisThe Lancet, 1993
- Effect of Serum Parathyroid Hormone and Bone Marrow Fibrosis on the Response to Erythropoietin in UremiaNew England Journal of Medicine, 1993
- The Lungs in UremiaSeminars in Respiratory and Critical Care Medicine, 1988
- Quantitative indices of clinical uremiaKidney International, 1979
- CHANGES IN BODY COMPOSITION IN ACUTE RENAL FAILURE 1Journal of Clinical Investigation, 1956